Fundraising Fox

Entegrion

Durham, US · Delaware corporation · 1 known investors

Entegrion develops a point-of-care viscoelastic coagulation monitoring system (VCM) for rapid hemostasis assessment in clinical settings including trauma, surgery, and obstetrics. The company serves clinicians in civilian and military medicine, with regulatory clearance in Europe.

BiotechDefense TechHealthtechMedical Devices

Founders & leadership

BV
Bert ValadaPresident and CEO
RM
Richard MartinNamed on SEC filing
SR
Susan ReyerNamed on SEC filing
MG
Michael GaligerNamed on SEC filing
JM
John MowellNamed on SEC filing
TE
Thomas EdwardsNamed on SEC filing
CR
Christopher RumanaNamed on SEC filing
PN
Patrick NashNamed on SEC filing
WB
W Brian GiblerNamed on SEC filing
PN
Pierre NoelNamed on SEC filing
RC
Robert CappsNamed on SEC filing
JT
J True MartinNamed on SEC filing

Investors · 1

Hatteras Venture PartnersResearch Triangle · $500K – $4M

Reported raises · per SEC filings

Form D private placements

$20.5M disclosed across 2 rounds · 2015–2022

▶$13.9MraisedJul 2022 · 87 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert CappsDirector
  • Pierre NoelDirector
  • Ronald SacherDirector
  • Brian GiblerDirector
  • Albert ValadaExecutive Officer, Director, Promoter
  • Christopher RumanaDirector
  • Patrick NashDirector
  • Thomas EdwardsDirector
  • Richard MartinExecutive Officer, Promoter
  • J. True MartinDirector
Offering amount
$20M
Amount sold
$13.9M
First sale
Jun 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.7MraisedMay 2019 · 73 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard MartinExecutive Officer
  • Susan ReyerExecutive Officer
  • Michael GaligerExecutive Officer
  • John MowellDirector
  • Thomas EdwardsDirector
  • Christopher RumanaDirector
  • Patrick NashDirector
  • W Brian GiblerDirector
  • Pierre NoelDirector
  • Robert CappsDirector
  • J True MartinDirector
  • Richard SacherDirector
Offering amount
$8M
Amount sold
$6.7M
First sale
Oct 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Eurofins Viracor5 shared keywordsEurofins Viracor is a specialty clinical diagnostic laboratory offering nearly 3,000 assays in infectious disease, transplant, allergy, invasive fungal, and immunology testing for critically ill and immunocompromised patients. It serves clinicians and transplant programs across the U.S. with molecular diagnostics and immunology testing.

Companies competing with Entegrion for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Velico® Medical Acquires Entegrion Inc’s Resusix Product Portfolioveli.co · Sep 2022Durham life science company Entegrion brings in $13.8M from 83 investors | WRAL TechWirewraltechwire.com · Jul 2022Entegrion Awarded up to $43.7 Million from Department of Defense for a Blood Product Technology - MassDevicemassdevice.com · Oct 2011RTP company Entegrion gets $43M Defense Department contractmedcitynews.com · Oct 2011Entegrion 6/7/2016 Capital Raise - Gaebler.com Venture Capital Databasegaebler.com

Frequently asked questions

What does Entegrion do?
Entegrion develops a point-of-care viscoelastic coagulation monitoring system (VCM) for rapid hemostasis assessment in clinical settings including trauma, surgery, and obstetrics. The company serves clinicians in civilian and military medicine, with regulatory clearance in Europe.
Who are Entegrion's investors?
Entegrion's investors include Hatteras Venture Partners.
How much funding has Entegrion raised?
Entegrion has disclosed $20.5M raised across 2 rounds.
Where is Entegrion headquartered?
Entegrion is headquartered in Durham, US.